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Background
In the UK, postnatal depression is more common in British South
Asian women than White Caucasion women. Cognitive–behav-
ioural therapy (CBT) is recommended as a first-line treatment,
but there is little evidence for the adaptation of CBT for postnatal
depression to ensure its applicability to different ethnic groups.
Aims
To evaluate the clinical and cost-effectiveness of a CBT-based
positive health programme group intervention in British South
Asian women with postnatal depression.
Method
We have designed a multicentre, two-arm, partially nested,
randomised controlled trial with 4- and 12-month follow-up,
comparing a 12-session group CBT-based intervention (positive
health programme) plus treatment as usual with treatment as
usual alone, for British South Asian women with postnatal
depression. Participants will be recruited from primary care and
appropriate community venues in areas of high South Asian
density across the UK. It has been estimated that randomising
720 participants (360 into each group) will be sufficient to detect
a clinically important difference between a 55% recovery rate in
the intervention group and a 40% recovery rate in the treatment-
as-usual group. An economic analysis will estimate the cost-
effectiveness of the positive health programme. A qualitative
process evaluation will explore barriers and enablers to study
participation and examine the acceptability and impact of the
programme from the perspective of British South Asian women
and other key stakeholders.
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Postnatal depression is a major public health concern because of its
negative effect on mothers, including relationship problems1,2 and
an increased risk of future depression. In the UK, postnatal depres-
sion is more common in British South Asian women than White
women.1,3 Postnatal depression also negatively influences the psy-
chological and cognitive development of children.2 Postnatal
depression is treatable,4,5 but women can be reluctant to disclose
symptoms and seek help because of stigma.6,7 Antidepressants can
be an effective treatment, but new mothers can be reluctant to use
them because of concerns about side-effects.4,5 Cognitive–behav-
ioural therapy (CBT) has been shown to be effective for postnatal
depression4,5 and is endorsed as a first-line treatment.8 However,
there is little empirical evidence for the adaptation of evidence-
based treatments, including CBT, to ensure their applicability to dif-
ferent ethnic groups.9,10 There is value in cultural adaptation and a
need to test the effectiveness of adapted interventions for ethnic
minority groups.11
The need for culturally adapted CBT
The positive health programme (PHP) is a culturally adapted group
CBT intervention for postnatal depression10 that has been devel-
oped by our research group in an exploratory randomised con-
trolled trial (RCT) (Exploratory RCT of a Group Psychological
Intervention for Postnatal Depression in British Mothers of South
Asian Origin; ROSHNI-D),12 and we were able to show the feasibil-
ity and acceptability of the present trial. A sufficiently powered trial
is needed to confirm the preliminary findings of ROSHNI-D, to test
both short- and longer-term outcomes, and to answer additional
research questions, including the cost-effectiveness of PHP. The
focus of the proposed study is a group CBT intervention for
British South Asian women with postnatal depression and psycho-
social difficulties. These women often live in low-income areas and,
because of their psychosocial problems, language and cultural bar-
riers, they are deemed ‘hard to reach’ and hard to engage. South
Asian people comprise the largest ethnic minority group in the
UK, representing around 7.5% (4 214 000) of the population,13
and have one of the highest birth rates in the UK. There are now pol-
icies that endorse the need for a range of effective therapies, includ-
ing psychotherapeutic treatments, that are culturally appropriate
and effective.14
Aims and hypothesis
The present trial, ROSHNI-2, aims to evaluate the clinical and cost-
effectiveness of the PHP intervention added to treatment as usual
(TAU), compared with TAU only, in British South Asian women
with postnatal depression. Roshni means light in Urdu/Hindi. The
primary hypothesis is that participants who receive PHP added to
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TAU will have reduced levels of postnatal depression, as measured
by the Hamilton Rating Scale for Depression (HRSD),15 compared
with participants receiving TAU only, 4 months after randomisa-
tion (end of intervention). HRSD scores at 4-month follow-up
will be the primary outcome measure. Costs associated with
health and social care resource use will be collected, and each par-
ticipant in the trial will be asked to complete the EuroQol EQ-5D
instrument at each follow-up, and these responses will be converted
to quality-adjusted life years (QALYs). Follow-up at 12 months will
provide evidence of long-term outcomes. A qualitative process
evaluation will explore barriers and enablers to study participation,
and examine the acceptability of PHP from the perspective of
British South Asian women, the impact of PHP on healthcare prac-
tice from the perspectives of general practitioners (GPs), and the
experiences of being trained in and delivering PHP from the per-
spectives of group facilitators.
Method
Design
This is a multicentre, two-arm, rater-blinded, partially nested RCT
with post-intervention (4 months) and 12-month follow-up, com-
paring PHP and TAU with TAU only, for British South Asian
women with postnatal depression. There is a likelihood that
because of the reciprocity between participants during the group
PHP intervention, they will respond in a similar manner and their
outcomes will be more alike than for women in different groups.
This leads to a clustering effect in the intervention condition
similar to that found in cluster randomised trials. The trial design
adopts a partially nested design with participants in the intervention
arm nested in therapy groups compared with the control arm par-
ticipants, who are not nested. Economic and process evaluations are
also embedded in the trial. The trial is registered with Clinicaltrials.
gov under registration number ISRCTN10697380.
Internal pilot phase
An internal pilot phase is integrated into the trial, with clear STOP/
GO criteria to prove viability to proceed to a full trial across all study
sites. Success criteria during the internal pilot study phase (months
5–14) will be gauged by recruitment of at least 200 participants. In
case this is not possible and we face difficulties in achieving the
target, we will look into the possible shortcomings and have a
‘rescue plan’ ready for deliberation by the Trial Steering
Committee and National Institute for Health Research approval.
STOP/GO criteria are as follows: GO if ≥180 participants are
recruited into the study (target minus 10%), implement rescue
plan if ≥120 (60%) but <180 (90%) participants are recruited into
the study, and STOP if <120 (60%) participants are recruited into
the study.
Setting
Participants are recruited from general practices, children’s centres
and other appropriate community venues in areas with a high South
Asian population across different locations in the UK (North-West,
Yorkshire, Midlands, London and Glasgow). Local principal inves-
tigators lead the conduct of the trial in each location, and are sup-
ported by the ROSHNI research team, all of whom, including
principal investigators, are trained in good clinical practice.
Study population
Participants are women of self-ascribed British South Asian origin
who live with their infant(s) aged ≤12 months, have postnatal
depression and will reside in the geographical area of the study
for the duration of their participation.
Inclusion criteria
The inclusion criteria are as follows: self-ascribed British South
Asian women as mentioned by the Office of National Statistics,13
aged 16 years or older; living with their infant(s), who are aged up
to 12 months; and meet the DSM-5 criteria for depression as con-
firmed by the Structured Clinical Interview for the DSM (SCID).16
Exclusion criteria
The exclusion criteria are as follows: diagnosed physical or intellec-
tual disability that prevents participation in the trial, postpartum or
other psychosis, or active suicidal ideation.
The exclusion criteria will not include ongoing use of anti-
depressant medication and earlier self-reported common mental
illness, including prior postnatal depression. Medication use will
be recorded in the baseline and follow-up assessments, and this
information will be considered at analysis.
Recruitment
Potential participants will be approached via GPs, children’s
centres, baby clinics, community centres, pharmacies and other
relevant locations. The study is promoted in each of these locations,
using materials that have been produced as a joint collaboration
with the patient group, and appear in English, Urdu, Hindi,
Bengali, Gujarati and Tamil. Community contact has already been
initiated through partnerships with voluntary sector organisations,
and the research team has started regular liaison meetings with the
local health visitors, GPs and children’s centres, for study promo-
tion. Specific inputs are also being taken from the community orga-
nisations related to trial design, recruitment methods and the
intervention content.
Participating GPs send a letter to all 6-week postnatal British
South Asian women informing them about the trial and inviting
them to take part. The letter includes the Patient Health
Questionnaire 9 (PHQ-9),17 a participant information sheet (PIS)
and a response slip. Potential participants are asked to complete
the PHQ-9 and consent-to-contact form, and return these to
their local study site via pre-paid envelope. Postal and telephone
reminders are sent to those who do not respond. In addition, GP
records are monitored for non-responders so that primary care
staff can remind women about the study at routine appointments.
When the PHQ-9 and consent-to-contact forms are completed
and returned, the research assistants will then make contact and
arrange to speak to the participant in a convenient location, to
provide further detail on the study and take consent.
Potential participants are also identified by the research team via
GP case records. With the GP’s permission, identified mothers are
contacted either directly by phone or in person, by a clinical
support officer, research nurse or GP administration staff, with
the support of a bilingual member of the research team. To
further ensure efficient recruitment, the research team visits local
children’s centres, baby clinics and other relevant locations, where
potential participants are invited to take part and are provided
with a PIS. Women who fulfil trial eligibility criteria are invited to
provide written informed consent for trial participation and base-
line assessment. All participants will be given ample opportunity
for clarifications and time to consider before signing the consent
form. The research teamwill advise participants that their participa-
tion in, or departure from, the trial does not affect any aspect of their
usual care. Once a patient has agreed to participate and signed a
consent form, they are then asked to complete the PHQ-9.
Participants who score ≥10 are eligible to progress to the second
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stage of assessment of eligibility. Mothers who score <10 on the
PHQ-9 at first screen will be again invited for a further assessment
after 12–16 weeks to complete the PHQ-9 again, if within the 52-
week postnatal period, to ascertain that later-onset postnatal depres-
sion is not missed.
The second stage of recruitment/assessment of eligibility is an
interview with the SCID.16 This is administered by trained
members of the research team at baseline to confirm the diagnosis
of depression. The SCID is a semi-structured interview that consists
of standardised diagnostic questions arranged in modules corre-
sponding to each DSM-5 Axis.16 The SCID has been used in a
large RCT of psychological intervention for postnatal depression
with a multicultural population in Canada.18 The PHQ-9 has
been translated and validated in Urdu.19 In cases where the SCID
confirms depression, women are asked to confirm consent to take
part in the study. In cases where the SCID does not confirm depres-
sion, these women are not randomised.
Our previous experience of research with British South Asian
mothers who have postnatal depression indicates that engagement
with participants’ families is fundamental to success, and that this
should begin at the time of screening. Therefore, at the potential
participant’s discretion, researchers will share details of the study
with other family members. Contact details will also be provided
for a bilingual senior investigator who will be available to converse
with the family if needed. The first study participant was recruited
on 8 February 2017.
Randomisation
Participants are randomised via an independent remote telephone
randomisation service based at the Manchester Clinical Trials
Unit. PHP is based on groups of between five and nine participants,
and randomisation is stratified by centre and will use a block size of
10–18, depending on the size of the site, so that five to nine partici-
pants are allocated to PHP plus TAU and five to nine participants
are allocated to TAU only. All efforts are made to ensure that the
time period between baseline assessment and randomisation will
be no longer than 4–6 weeks. The GP is informed about their
patient’s participation in the trial and treatment allocation by a
letter, to be kept with the participant’s medical notes.
It is not possible to blind participating mothers, their GPs or
practice health visitors to treatment group. Researchers who are
blind to treatment allocation will collect the outcome measures.
To minimise selection bias and maximise external validity, we will
recruit mothers across geographies in the UK and aim to keep the
exclusion criteria to a minimum.
Intervention
PHP is a manual-assisted, culturally adapted, group psychological
intervention delivered by two trained, bilingual facilitators (one
lead facilitator and a co-facilitator). PHP is based on the principles
of CBT, and has been found to be acceptable by participants in pre-
vious studies of postnatal depression in British South Asianwomen.10
In ROSHNI-2, 12 group PHP sessions are delivered in total; sessions
are delivered once a week for the first 2 months, and then fortnightly
for the following 2 months. Each group session lasts 60–90 min, and
at the start of each session participants are reminded about confiden-
tiality and are assured by facilitators that any disclosures they make
will remain confidential, with the exception of any intentions of
harming oneself or others. The sessions covered within the PHP
include identifying the pressures and expectations of being a South
Asian woman, understanding and managing self-esteem, ‘keeping
upwith the Chaudhry’s’, exercise and looking good, religion and spir-
ituality, relaxation and ‘taking time out’, assertiveness and confidence
building, breaking social isolation and building social networks, and
practising CBT techniques and assessing change and developing
relapse prevention plans.
The processes through which PHP was culturally adapted are
described in detail elsewhere.10,12 The PHP manual is available in
English, Urdu, Hindi, Bengali, Gujarati and Tamil. Before each
group starts, facilitators are matched to groups according to lan-
guages most commonly spoken by group participants. All facilitators
are fluent in English and one or more of the study languages. Our
earlier findings point out that when working with diverse popula-
tions, the venues where the intervention is delivered should be kept
as neutral as possible and ‘not owned’ by a specific ethnic or religious
group.10 Therefore, PHP is delivered at children’s centres and other
community venues, as these are considered more acceptable to the
British South Asian community than going for ‘therapy’ or ‘treat-
ment’ in a medical setting. Transportation, child care and refresh-
ments are provided to facilitate mothers’ attendance at group
sessions. Health Research Authority guidance states that payment
to participants in therapeutic research, in addition to reimbursement,
are permissible, as they may reduce potential power imbalances by
making participation seem less like a favour to a healthcare profes-
sional or researcher.20 Furthermore, in the UK it is standard practice
to pay healthy volunteers and patient volunteers, therefore not paying
others who also contribute to research would be unfair, and the ben-
efits that participants may receive from the intervention do not mean
that they should be barred from receiving payment. Participants are
reimbursed with a £10 ‘love2shop’ voucher for their time and their
travel expenses are also reimbursed. The intervention group will con-
tinue to receive routine assessment and management by the primary
care team. With the written informed consent of participants, a few
groups sessions are recorded for quality checks.
Training, supervision and competency assurance
PHP facilitators are of different backgrounds and have varying
levels of experience of delivering psychological interventions in
the British South Asian community. Each facilitator received two
full days training, which is delivered by PHP trainers who are
mental health professionals and therapists by background (K.L.,
N.A.). The content of each PHP session is covered during training,
and time is also spent on non-therapeutic specific skills, including
engaging with participants, controlling PHP groups, listening
skills and safeguarding. Didactic and Socratic teaching methods
are used in PHP training and these are facilitated with presentations,
group discussions and role-play methods. At least one out of 12 ses-
sions is observed by PHP trainers, following which constructive
feedback is provided and any areas that need improvement are high-
lighted. Monthly supervision is conducted by the PHP supervisory
team and is available between sessions if deemed necessary by PHP
trainers or requested by group facilitators. Supervision is conducted
over the phone or via Skype in most instances, to account for the
geographical distribution of groups and facilitators.
Treatment as usual
TAU includes participating GPs carrying out routine assessment
and management and may involve ongoing monitoring,
Improving Access to Psychological Therapies/other services referral
and antidepressant prescription.
Outcome measures
Outcome measure data is collected at two time points: the end of
intervention at 4 months, and 12 months after randomisation.
The SCID is not repeated at the 4-month follow-up as it is used
only as a diagnostic measure in ROSHNI-2, to establish diagnosis
of depression (Table 1 and Fig. 1).
ROSHNI‐2 study protocol
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Primary outcome measure
At the 4-month follow-up, the primary outcome measure is the
HRSD,15 which is a valid and reliable measure of severity of depres-
sion. A score of ≤7 on the HRSD will indicate remission/recovery
from depression.
Secondary outcome measures
Secondary outcome measures are as follows:
(a) Treatment response will also be measured with the HRSD;
treatment response criteria is a reduction of ≥50% in the
HRSD baseline score of the participants.
(b) PHQ-917: valid and reliable self-report measure of severity of
depression; Urdu and Bengali versions of the PHQ-9 have
been validated.21
(c) Generalized Anxiety Disorder-7 (GAD-7)22: a valid and reli-
able self-report measure of severity of anxiety; an Urdu
version of the GAD-7 has been validated.23
(d) Parenting Sense of Competence24: a valid and reliable self-
report measure of parental competence;25 Parental competence
is measured on two dimensions of satisfaction and efficacy; the
questionnaire has 16 items (nine on satisfaction and seven on
efficacy) and is scored according to a six-point Likert scale,
ranging from ‘1, strongly disagree’ to ‘6, strongly agree’.
(e) Social functioning12: a self-report measure rating difficulty in
completing ten items concerning daily function; the question-
naire is scored according to a five-point Likert scale, ranging
from ‘0, no difficulty’ to ‘4, often can’t do the task’.
(f) Improving Access to Psychological Therapies Patient
Experience Questionnaire26: a valid and reliable self-report
measure of an individual’s experiences of the intervention
they participated in.
(g) Ages and stages questionnaires27: a valid and reliable parent-
completed measure of childhood development; this series of
11 questionnaires each include 30 closed questions on five
domains of child development; mothers will finish the ques-
tionnaire both at baseline and 12-month follow-up.
(h) EQ-5D-3L:28,29 a health status measure, which has five dimen-
sions (mobility, self-care, usual activity, pain/discomfort,
anxiety/depression); participants can rate themselves as
having no problems, some or moderate problems or extreme
problems (for pain/discomfort and anxiety/depression
domains), or unable to do an activity (self-care and usual activ-
ity domains or confined to bed (mobility domain).
(i) Economic Patient Questionnaire (EPQ): health service use will
be captured using an EPQ; in addition to the National Health
Service (NHS) and social care, cost to the participant for ser-
vices will also be collected; if women in either arm of the
trial are receiving any other treatment, this information will
be captured here.
All measures are available in Urdu, Hindi, Bengali, Gujarati and
Tamil.
Sample size
We will recruit 720 participants and randomise 360 into each arm.
With 40 closed groups of nine and 360 controls, the trial will have
90% power to detect a clinically important difference between a
55% recovery rate in the intervention and a 40% recovery rate in
the control, assuming an intraclass correlation (ICC) for group
treatment of 0.05, a 75% follow-up and a 5% significance level.
The sample size calculation and data analysis take into account clus-
tering because of the partial nested design. Statistical methods for
the partially nested design have been discussed in other publica-
tions.30 Peer-reviewed work by scholars evaluating psychological
treatments for postnatal depression points out that for the effect
to be considered clinically meaningful, there needs to be a 20%
absolute decrease in the number of mothers with depression post-
treatment, endorsing the need to develop and implement such
treatments. On the recommendation of the funding panel, we will
be powered to detect a difference of 15% in the primary outcome
between the two randomised arms. Our exploratory trial suggests
that a 75% follow-up rate can be achieved at 4 months. Assuming
this follow-up rate and an initial group size of nine women per
group, the mean group size will be 6.75 women.
There is not enough reliable data related to the magnitude of
therapy group clustering when evaluating psychological treatments
for postnatal depression. Barrowclough et al give 30 estimates of the
ICC for a group therapy, ranging from 0 (95% CI 0–0.29) to a
maximum of 0.257 (95% CI 0.02–0.67), with a mean of 0.044 and
median of 0.31 From the width of the confidence intervals, there is
appreciable uncertainty regarding these estimates. An ICC of 0.05
approximates to a moderate Cohen effect size (0.5) and this is
close to the mean of the estimates from Barrowclough et al.31 The
study is robust against larger values of the intracluster correlation
for group treatment. For example, if the intracluster correlation
coefficient is as large as 0.1, power will still be 86.7%. We therefore
believe that the value of 0.05 is a reasonable choice of ICC to use for
sample size calculation. In some smaller sites, to reduce the wait for
participants for PHP groups to start smaller PHP groups with five to
six (10–12 SCID-positive) participants may be run. Reducing the
group size to an average of five participants and recruiting a
larger number of groups would further increase the power to 91%.
Statistical analysis
We will use intention to treat analysis. Statistical analysis will be
carried out with a logistic random effects model to estimate the
odds ratio of recovery between treatment arms, with additional cov-
ariates of centre, baseline severity of depression and education (<8
Table 1 Schedule of assessments
Procedures
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GAD-7 X X X















PHQ-9, Patient Health Questionnaire 9; HRSD, Hamilton Rating Scale for Depression;
SCID, Structured Clinical Interview for the DSM; GAD-7, Generalized Anxiety Disorder-7:
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years, ≥8 years). The analysis will be used for both the primary
outcome measure (recovery at 4 months, end of intervention) and
the further outcome (at 12 months). Random intercepts will be
included for the therapy groups, with control participants treated
as clusters of size 1, using the methods described by Roberts and
Roberts30 for the analysis of a partially nested trial.
The treatment effect for quantitative secondary outcome mea-
sures will be estimated with a similar approach, with a linear
random effects model and a random intercept for therapy group.
Baseline value of the measure, centre, parity and educational level
will be included as covariates. Statistical analyses will investigate















Excluded/withdrew before randomisation (n =)
PHQ-9 high scores
•  Declined to participate (n =)
•  Other reasons (n =)
•  SCID-negative (n =)
•  Refused (n =)






















Assigned to control group
(n =)
Fig. 1 Consolidated Standards of Reporting Trials study flow diagram.
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random effects model, as non-response may be clustered by therapy
group. Sensitivity analysis will be carried out under a range of
assumptions regarding missing data informed by the analysis of
non-response.
Economic evaluation
Measurement of resource use and costs
The primary economic analysis will use the perspective of the UK
NHS and personal social services,32 and costs will include those
associated with use of NHS and social care primary, secondary
and community based services. We believe that direct costs are
mainly related to the use of in-patient, out-patient and clinic ser-
vices at the beginning of the trial and related follow-ups.
Sensitivity analysis will take a broader cost perspective to include
voluntary care services as well as patient and family expenses. An
EPQ data collection tool developed by the applicants will be used
to collect service use data. A similar form has been used in an
earlier completed trial of complex behavioural and psychological
interventions in mental health.33 All participants will be asked to
complete the EPQ at enrolment and every follow-up assessment.
Details to be collected include whether the participant has been
admitted to psychiatric or non-psychiatric in-patient care or
whether they used out-patient hospital services, including the
names of the hospitals attended. The gathered information will be
used to identify the relevant hospitals and patient records to
extract more details of each admission and resource use by the par-
ticipants. The EPQ will also ask for other non-hospital based health
and social care and third sector services use by participants.
Information related to any additional support from faith healers
and Imams, and any out-of-pocket spend, will also be collected.
To calculate the cost of each component, national unit costs will
be used and each item of resource use will be multiplied by the unit
cost specific to that item. Hospital services will be costed by using
the relevant national reference costs for each type of admission
data published annually by the Department of Health.34 Unit
costs for medications will be obtained from the British National
Formulary. Other sources of unit costs for other services will be
based on unit costs of health and social care published annually
by the Personal Social Services Research Unit, University of Kent.35
Measurement of health outcomes
The measure of health benefit for the primary economic analysis
will be QALYs estimated from the EQ-5D-5L. The EQ-5D-5L is a
validated, generic health status measure, designed to compare
health outcomes across diseases. The National Institute for Health
and Care Excellence recommends the QALY and the EQ-5D-5L
as measures for economic evaluations.32 The EQ-5D-3L responses
will be used to generate utility values for each assessment. The eco-
nomic analysis will use the value set for the UK general population,
since alternative value sets relevant to South Asian populations are
not available.36 The utility scores for each participant from baseline
to the end of follow-up will then be used to calculate QALYs as
follows:
QALY ¼ Σ[(Ui þ Uiþ1 þ Uiþ2)=3] × (tiþ2  ti) over i ¼ 0& 1,
where U is utility and t is time at assessment. The time between
assessments is the time from baseline to 12-month follow-up (i = 2).
Cost-effectiveness analyses
The cost and health benefit data will be analysed by treatment
allocated and include data for all participants whether or not they
completed planned care. However missing data are inevitable
from loss to follow-up or missing observations. Single imputation
will be used for missing baseline measures of cost, utility and clinical
indicators,37 but not missing demographic data. An indicator for
missing demographic data will be used.
The final imputation strategy will depend on the pattern of
missingness in the data. If the data approximate missing at
random or missing completely at random, multiple imputation
from available data will be used, as recommended by Faria
et al.38 Literature review and regression analysis of pooled data
(masked to treatment allocation) will be used to identify key
baseline and follow-up variables associated with costs and
QALYs to include in the imputation models. The data will be
imputed by category of cost and EQ-5D domain to make best
use of available data.
Primary analysis
Descriptive analyses of costs and summary health benefit measures
will be reported for the intervention and comparator for the com-
plete case and imputed data at baseline and follow-up assessment
points. Regression analysis will estimate net costs and QALYs of
the intervention. Covariates to account for factors that influence
costs or QALYs will be identified from published literature, supple-
mented with analysis of pooled baseline data.
The regression-based estimates of costs and outcomes will be
bootstrapped to replicate 10 000 pairs of incremental cost and
QALY outcomes of the intervention. The distribution of pairs of
net costs and QALYs will be plotted on the cost-effectiveness
plane.32
Incremental cost-effectiveness ratios estimate the net cost per
QALY gained by an intervention, and raise the question whether
that cost is worth paying. To address this, the ICERs are compared
with how much decision makers may be willing to pay for an
additional QALY. However, the UK has no universally agreed
cost-effectiveness threshold. The National Institute for Health
and Care Excellence39 has previously suggested a threshold of
£20 000 to £30 000 per QALY. However, other commentators
suggest this may be lower.40,41 Reflecting this lack of consensus,
the monetary value of simulated QALYs will be estimated across
the range of £0–£30 000 willingness-to-pay thresholds. This
recognises that decision makers may not be willing to pay for an
additional QALY (in other words, they may only seek the lowest
cost option) or could be willing to pay up to £30 000 for an
extra QALY gained. To estimate the likelihood the intervention
is cost-effective for the primary analysis, a willingness-to-pay
threshold of £15 000 (the mid-point of the £0–£30 000 range)
will be used.
Cost-effectiveness acceptability curves will be generated to
show whether the likelihood that the intervention is cost-effective
at each willingness to pay value is above 50%. As decision makers
increase what they are willing to pay for an extra QALY, the
additional health benefits from an intervention become more
valuable, and it achieves net benefit in a bigger proportion of
the 10 000 replicates.
Sensitivity analyses
Sensitivity analyses will be conducted to assess the effect of struc-
tural uncertainty introduced by the design of the economic evalu-
ation. These analyses include re-estimating the results, using the
primary clinical measure as the measure of health benefit; different
approaches to missing data, such as use of complete cases only, or
indicator values; broader cost perspective; and predictions of costs
and QALYs beyond the 1-year trial horizon (for example, over
longer time horizons of 5 and 10 years).
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Qualitative process evaluation
Although RCTs are the gold standard for establishing the effective-
ness of complex interventions such as PHP, quantitative data does
not provide insights into how complex interventions might be
replicated or insights into how these interventions are experienced
by patients. Process evaluations investigate the ‘reach’ of interven-
tions.42 Exploring the mechanisms through which interventions
bring about change is crucial to understanding how the effects of
the specific intervention occurred, and how these effects can
inform the development of similar future interventions.43
To learn lessons for recruitment and acceptability of the inter-
vention for the full trial, during the internal pilot phase of the
trial, we will examine barriers to recruitment and retention and
also look at personal experiences of the women who withdrew
from participation in the trial. We will invite women and PHP facil-
itators to participate in a semi-structured interview.
In the full trial (following successful completion of the pilot), we
will conduct interviews with women who have completed the inter-
vention to explore acceptability of the PHP, and women who
enrolled in the trial but only attended one or none of the PHP ses-
sions. We will interview group facilitators who have delivered the
PHP intervention, and GPs who have engaged with, and referred
women to, the ROSHNI trial, Semi-structured interviews will be uti-
lised to explore views on the perceived feasibility, acceptability and
sustainability of the PHP in the management of postnatal depres-
sion, in this patient group, in primary care.
Topic guides have been developed for the pilot phase by the
research team following review of the literature and discussion
with patient and public advisors, and will be iteratively developed
and refined during the pilot and then in the main trial as analysis
progresses.
The objectives of the qualitative study are to explore early bar-
riers and enablers to study participation, to optimise ongoing trial
recruiter training and trial recruitment rates (pilot); identify
reasons for continuing or not continuing with the study (pilot
and full trial); examine the acceptability of the group intervention
from the perspective of British South Asian women (pilot and full
trial); explore views of the GPs on the group psychological interven-
tion and its impact on practice (full trial); and explore perspectives
of group facilitators (group psychological intervention deliverers)
about training and delivery of the intervention (pilot and full trial).
Participants are given information about the qualitative aspect
of the trial during the baseline assessment and also asked for
consent to being contacted by the research team to participate in
an interview. Perspective interviewees are identified via a purposive
sampling strategy, and to achieve the purpose of inviting patients
from different socioeconomic backgrounds, ages and native lan-
guages, maximum variation sampling techniques are used and
patients are sampled from across the five centres for the trial.
Interviews are conducted with women once the primary outcome
measure has been obtained (4 months post-randomisation) so as
to avert bias likelihood that might be introduced by the supportive
role of the qualitative interview. Participant interviews will be con-
ducted within 8 weeks of their primary outcome measures being
collected.
In the full trial, up to 20 women who participated in the group
sessions will be interviewed with the aim of examining at length the
acceptability of group meetings, viewpoints on discussing personal
problems in front of other participants, views on the involvement of
the group facilitator, family’s perspective on the participants’
attendance and the effect on the current situation. Interviews will
also be conducted with up to 20 women who dropped out of the
study after one or no session, to better understand their reasons
for not continuing with the sessions.
Interviews will also be conducted with group facilitators (up to
15) to investigate barriers and enablers to the group work. GPs par-
ticipating in the trial (up to 15, across study sites) will be invited to
participate in interviews to further our understanding on the man-
agement of British South Asian women with postnatal depression
and the impact of the intervention on routine practice work.
The researcher will contact the trial participants, GPs and group
facilitators, check consent, and arrange an appointment to interview
them at a time and place convenient to the respondents (e.g. home,
telephone, general practice). Before the face-to-face or telephone
interviews, written consent to participate in the interview will be
obtained. Telephone interviews, lasting up to an hour, will be con-
ducted with suitable equipment and infrastructure. The researcher
will obtain consent from the participant to record and transcribe
verbatim the interview. Where the participant does not speak
English as their first language, interviews will be carried out in the
participant’s preferred language and later translated for analysis.
Existing recommendations for conducting and reporting cross-
language qualitative research will be used where applicable,43
including pilot testing the interview guide translation before carry-
ing out the interview, independent verification of translated inter-
views, and detailing the role and credentials of the translator in
any outputs.
Data analysis
Thematic analysis with principles of constant comparison44 will be
conducted. This will be followed by framework analysis, which
allows for the inclusion of a priori as well as emergent concepts.45
Framework analysis is effective for using data collected through
open-ended questioning and focusing it toward a particular
research question in health services research, particularly when a
large body of data has been generated.
There are five phases of the framework method of analysis,
which are interlinked to form a rigorous framework: familiarisation
with the data; identifying a thematic framework; indexing; charting;
and mapping and interpretation. These phases enhance under-
standing and interpretation of the data from descriptive accounts
to a conceptual explanation.45,46
The framework analysis will be sensitised by the use of the
theoretical framework of acceptability.47
Regular meetings between the three researchers (S.A., R.M. and
J.B.) who are responsible for independently carrying out data
coding, and their supervisors (C.A.C.G. and P.Bee.) will be orga-
nised to ascertain that the emerging codes remain grounded in
the original data.
Public and patient involvement and engagement
Patient and public involvement and engagement was of great benefit
to the recruitment and retention strategies used during the
ROSHNI-D trial, and for dissemination.12 As such, patient and
public involvement and engagement activity is planned throughout
the trial.
Initial discussions with key stakeholders from institutions to
hold workshops in temples, gurudwaras, mosques, churches, and
children’s and community centres were held so that we can
further community engagement. Workshops provide information
on depression in general, and particularly postnatal depression in
British South Asian women. We record and take into account feed-
back from workshops, with particular focus on how to address
stigma. The advisory group members provide a crucial support
when it comes to community engagement. The advisory board
also engages patients with trained expertise in research methods
and have trained over 50 patients and carers in research methods.
ROSHNI‐2 study protocol
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Seminal work by Lovell and colleagues has a good practice citation
by the National Institute for Health and Care Excellence.48
Ethics
The research team brings with it an enriching clinical and research
experience, and has hands on training in managing challenging
situations in research interventions and interviews. We are
cognisant of the fact that some respondents can be vulnerable,
therefore we will make sure we provide adequate supervision of
the researchers, keeping in mind safeguarding participants’
welfare. Timely and regular supervision will be carried out during
the entire course of the project for all research staff and group facil-
itators, including training the staff in good clinical practice and
safeguarding (study ethical approval number: IRAS 187851).
Clear guidelines relating to a distress policy have been formu-
lated, keeping in mind the potential effects of conducting research
with this group. A distress policy has been formulated. A number
of practical measures are taken to minimize distress and risk to
participants; for example, when obtaining consent, researchers
clarify to participants that they are able to take time in answering
questions.
Monitoring, recording and reporting of adverse events will be
managed with the local principal investigator, the participant’s GP
and health visiting team, and in line with each Trust’s policy. The
Clinical Trials Unit will carry out audits and safety monitoring.
Safety protocols have been designed and developed to ensure that
safety of research staff, participants and their families remain safe
when making contact, conducting research and afterward. This
includes researchers confirming that they are speaking with the par-
ticipant and not leaving information with other household
members, asking participants in qualitative interviews how they
are feeling at the end, and signposting relevant support when neces-
sary, and researchers following lone-worker policy.
Progress with ROSHNI-2 internal pilot
The internal pilot was designed to test the ability of the four add-
itional centres to recruit to time and target, with a target recruitment
of n = 180−200 patients within a 12-month period (November 2016
to October 2017), with a minimum of 120 patients for the trial to
continue. Because of a variety of delays, all sites started late, and
thus the recruitment period for the internal pilot centres was
extended until June 2018.
Recruitment of more than theminimum 120 patients during the
internal pilot up to 30 June 2018 was achieved, and the internal pilot
target wasmet to ensure the study continued recruitment. Following
the internal pilot, the decision was made to close one site and the
resource saving to be redistributed to capitalise on the greater
recruitment opportunity in other recruitment sites. The Glasgow
site was not able to recruit sufficient number of participants
because of low British South Asian birth rates.
Summary
This study is unlike other comparable mental health studies or
even physical health trials with British South Asian participants,
given the stigma of mental health in the different South Asian
communities and the difficulty in engaging young women, par-
ticularly in households often dominated by men and older
people. Each site requires its own culturally adapted approach
for community engagement and not just one approach. Despite
its challenges, the internal pilot study has been successful in dem-
onstrating the viability of progression to a full trial by ensuring
that trial processes relating to recruitment, randomisation, treat-
ment and follow-up assessments now work well. In addition, the
value of the internal pilot period has been recognised in reflecting
on lessons learned. This allowed us to improve the management,
communication, processes and efficiency of all trial activity, thus
optimising outputs of all remaining centres as we moved into
the full trial.
Dissemination
The results of the study will be published in peer-reviewed journals
and presented at national and international conferences. Study
findings will also be disseminated to local and national groups in
partnership with patients, carers and local voluntary organisations
such as MIND, Ethnic Forum and Social Action Forum. Results
will also be publicised through a website, short films and our
media partners, including Pendle Radio and Asian Image, and
through local temples, mosques, churches and community
centres, using our existing networks such as the Black and
Minority Ethnic Network Lancashire. Information about the
research will also be disseminated to the British Council, which
has extensive networks not only within the UK, but also overseas.
We will also take advantage of our expertise in working with the
NHS and voluntary sector, and share the training needs and infor-
mation of the culture specific needs of this group. Extensive consult-
ation rounds related to the rich knowledge gained from the trial will
be shared with NHS stakeholders and with relevant local, regional
and national policy makers and commissioners, to better inform
decision-making and service improvements. Consultations will
also include patients from the local communities and trial partici-
pants. A low-cost PHP manual and how-to ‘tool kit’ will be a
crucial output of the study.
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